Jennifer Houp

663 total citations
8 papers, 465 citations indexed

About

Jennifer Houp is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Jennifer Houp has authored 8 papers receiving a total of 465 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Hematology and 4 papers in Oncology. Recurrent topics in Jennifer Houp's work include Multiple Myeloma Research and Treatments (5 papers), Histone Deacetylase Inhibitors Research (5 papers) and Protein Degradation and Inhibitors (4 papers). Jennifer Houp is often cited by papers focused on Multiple Myeloma Research and Treatments (5 papers), Histone Deacetylase Inhibitors Research (5 papers) and Protein Degradation and Inhibitors (4 papers). Jennifer Houp collaborates with scholars based in United States, France and Greece. Jennifer Houp's co-authors include Kenneth C. Anderson, Thorsten Graef, Hartmut Goldschmidt, Meletios Α. Dimopoulos, David S. Siegel, Christine K. Gause, Joseph Eid, Linda Sun, Kenneth Emancipator and Laura Q.M. Chow and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jennifer Houp

8 papers receiving 454 citations

Peers

Jennifer Houp

ONCOL

MB

HEMAT

IMMUN

PRM

Patrick Chun United States

Dina Ali Sweden

Susanne Beck Germany

Alfredo Zito Italy

Soumi Lahiri United States

Sungwoo Ahn South Korea

Xinyi Cindy Zhang United States

Leutz Buon United States

Ellen Ingalla United States

S. Hayley United States

Patrick Chun United States

Jennifer Houp

243 ×0.8

ONCOL

142 ×0.5

MB

47 ×0.2

HEMAT

73 ×0.7

IMMUN

101 ×2.1

PRM

Citations per year, relative to Jennifer Houp Jennifer Houp (= 1×) peers Patrick Chun

Countries citing papers authored by Jennifer Houp

Since Specialization

Citations

This map shows the geographic impact of Jennifer Houp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Houp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Houp more than expected).

Fields of papers citing papers by Jennifer Houp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Houp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Houp. The network helps show where Jennifer Houp may publish in the future.

Co-authorship network of co-authors of Jennifer Houp

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Houp. A scholar is included among the top collaborators of Jennifer Houp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Houp. Jennifer Houp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Siegel, David S., Meletios Α. Dimopoulos, Sundar Jagannath, et al.. (2016). VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 16(6). 329–334.e1. 23 indexed citations

2.

Nanda, Rita, Laura Q.M. Chow, E. Claire Dees, et al.. (2015). Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Cancer Research. 75(9_Supplement). S1–9. 87 indexed citations

3.

Nanda, Rita, Elizabeth R. Plimack, Elizabeth Claire Dees, et al.. (2014). A phase Ib multicohort study of MK-3475 in patients with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). TPS3119–TPS3119. 3 indexed citations

4.

Seiwert, Tanguy Y., Barbara Burtness, Jared Weiss, et al.. (2014). A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer.. Journal of Clinical Oncology. 32(15_suppl). 6011–6011. 96 indexed citations

5.

Dimopoulos, Meletios Α., David S. Siegel, Sagar Lonial, et al.. (2013). Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. The Lancet Oncology. 14(11). 1129–1140. 181 indexed citations

6.

Dimopoulos, Meletios Α., Sundar Jagannath, Sung‐Soo Yoon, et al.. (2011). Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial. Blood. 118(21). 811–811. 32 indexed citations

7.

Siegel, David S., Meletios Α. Dimopoulos, Sung‐Soo Yoon, et al.. (2011). Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial. Blood. 118(21). 480–480. 36 indexed citations

8.

Richardson, Paul G., Donna Weber, Constantine S. Mitsiades, et al.. (2010). A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population. Blood. 116(21). 1951–1951. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact